On many different measures, the United States is an outlier in the developed world. The world's single remaining superpower and largest economy, the USA is nonetheless unique among industrialized countries in failing to provide healthcare for all its citizens. A key issue is the way health care is seen as a tradable, and thus potentially pro®t-making, commodity 1 . This perception has been strengthened greatly as for-pro®t healthcare organizations have been displacing not-for-pro®t ones. During the 1990s, healthcare was among the fastest growing sectors on the New York stock exchange 2 . Notable among the strategies of the new participants in the market were reduction of coverage (for example, refusal to pay for inpatient stays for normal deliveries or mastectomies) and cream-skimming (denial of cover to those individuals likely to incur the greatest costs). The number of uninsured has increased to about 45 million 3 , healthcare costs have continued to rise, and, at least until recently, corporate pro®ts greatly exceeded growth in the overall economy. In other industrialized countries healthcare is seen quite differently. Although there may be some private sector involvement, it is seen generally as something that is provided for all, either by the state or by non-pro®t bodies, such as German sickness funds or Dutch hospitals 4 . This difference has been of little concern to Europeans, Canadians, Japanese and others; but perceptions may change as discussions in the international arena begin to challenge the rights of countries to organize their healthcare systems as they think ®t.
The World Trade Organization (WTO) meeting in Seattle, at the end of 1999, broke down acrimoniously, as developing and developed countries exchanged accusations of ignoring one another's interests. The talks collapsed against a backdrop of violence involving the Seattle police and thousands of anti-WTO demonstrators from across the world. The demonstrators had a wide range of concerns, many of which are related to health. These include some where the link is direct, such as the provisions of the TRIPS (Trade Related Aspects of Intellectual Property Rights) agreements, which have important implications for access to pharmaceuticals 5 and for the ownership of drugs derived from indigenous plants 6 ; similar issues arise from attempts to constrain the right of national governments to prohibit imports of, for example, genetically modi®ed foods or hormone treated beef 7 . Others are less direct, such as the WTO ruling against the right of some European countries to give preference to bananas grown in their former colonies in the Caribbean, where there are fears that the loss of banana production will leave subsistence farmers with few options except production of narcotics 8 .
Although healthcare is unlikely to have been at the forefront of the minds of demonstrators or delegates, this is an area where issues of global trade could soon move to centre stage. In the UK there are fears that the Government could ®nd itself increasingly impotent in the face of a gradual move to an American model of healthcare 9 . Until now, the major supranational in¯uence on domestic policy in the UK has been the body of European law 10 . Formally, healthcare is explicitly excluded from the competence of the European institutions 11 but, as the health system operates within a wider economy, it has been subject to several important provisions. These include the directive on transfer of undertakings that greatly complicated the Government's policy on competitive tendering for domestic services in hospitals and, more recently, the Working Time Directive, which will have major implications for staf®ng of district hospitals 12 . The previous Government did establish an internal market in the National Health Service, but this was a highly constrained market that precluded the major participants from making pro®ts that could be distributed to shareholders, as well as placing substantial obstacles in the way of market entry or exit 13 . That it could do so without interference from the European Union was because of the principle, in European Law, that only those activities deemed to be`services' are included within its scope. This principle derives from a case involving the German education sector, in which it was held that services provided as part of a national system, where the recipient obtains them without charge or pays for them out of a grant from the state or is later reimbursed, should not be considered to be services within the meaning of the European Treaties 14 . Clearly some healthcare systems exist just on the edge of this de®nition, especially where governments have sought to increase participation by the private sector, as in The NetherlandsÐwhere a committee has recently warned the health minister that a greater role for private insurance funds could open up the healthcare system to foreign for-pro®t companies and ultimately undermine the existing system of solidarity 15 . Nonetheless, European healthcare has essentially remained a national issue.
Had the discussion between governments in Seattle taken place, one of the issues that they would have addressed would have been revision of the General Agreement on Trade in Services (GATS). This includes many sectors where there is now widespread consensus about the bene®ts of free trade, such as transport and telecommunications, but also sectors where the bene®ts are less clear, such as health. Although, formally, membership of the WTO consists of national governments, industry representatives exert great in¯uence, often as members of EDITORIAL 109 governmental delegations. Under pressure from a domestic healthcare market whose pro®ts have been falling 16 , the US Government is now striving aggressively to open up the healthcare systems of other countries to international competition. In doing so, it has the advantage of a much wider de®nition of a service, as`one which is supplied neither on a commercial basis, nor in competition with one or more service suppliers'. The potential impact of these discussions on healthcare has been explored in a brie®ng note prepared by the WTO Secretariat 17 . This begins by stressing the centrality of the pursuit of ef®ciency, although the authors later concede that they`may be criticized by health policy experts for over-emphasizing trade and commercial policy objectives and not paying suf®cient attention to fundamental equity and other social policy considerations'. The authors identify opportunities for increased cross-border trade in healthcare, ranging from tourists obtaining healthcare if they become ill while abroad to the establishment of foreign-owned healthcare facilities. The Secretariat note that many aspects of healthcare provision remain excluded from existing WTO regulations but critics argue that the agreement by governments tò enter into successive rounds of negotiations . . . with a view to achieving a progressively higher level of liberalisation' will ultimately lead to much more competition in the healthcare sector, with greater involvement of the private sector 1 .
It is, of course, arguable that a more competitive environment would be bene®cial to the NHS. Enthoven maintains that many of the failings of the 1990s reforms can be attributed to government's failure to free up the market 19 . This application of economic theory ignores the empirical lessons from countries with much greater private ®nancing and provision than is the case in Europe 21, 22 . The search for pro®t creates huge incentives to avoid risk, by excluding those most likely to incur high costs, whether de®ned on grounds of medical history, area of residence or, potentially, genetic make-up. Individuals concerned must either forego treatment or, more likely, become a charge on the residual state sector. Unless there are much more stringent rules on monopolistic behaviour than exist in the UK at present, there are powerful incentives to engage in anticompetitive behaviour, forming cartels and driving prices up. Undoubtedly some providers would bene®t, such as healthcare workers in specialties that are in high demand from patients who can pay for them, as well as the pharmaceutical and medical technology industries 22 . But many people would be losers, especially those living and working in deprived or remote areas.
In many ways, Seattle was a turning point. International trade negotiations achieved a level of public visibility that those involved could never have imagined previously. The threat to the European model of healthcare, based on solidarity, is not yet a reality, but it is one that Ministries of Health should take very seriously. There is a strong argument for international action to regulate healthcare that crosses bordersÐbut this action should protect the interests of patients rather than shareholders. 
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